Mirae Asset Global Investments
KLRS

Mirae Asset Global Investments’s Kalaris Therapeutics KLRS Stock Holding History

Mirae Asset Global Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-527
Closed -$48.6K – 2602
2024
Q1 		$48.6K Buy
+527
New +$8.6K ﹤0.01% 2424
2023
Q4 		– Sell
-643
Closed -$31.8K – 2614
2023
Q3 		$31.8K Buy
643
+24
+4% +$1.64K ﹤0.01% 2558
2023
Q2 		$48.4K Sell
619
-8
-1% -$760 ﹤0.01% 2593
2023
Q1 		$56.8K Sell
627
-2
-0.3% -$255 ﹤0.01% 2504
2022
Q4 		$74.3K Buy
629
+1
+0.2% +$170 ﹤0.01% 2493
2022
Q3 		$114K Buy
+628
New +$97.9K ﹤0.01% 2474

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments's KLRS Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 527 shares — an estimated $48.6K sold.

Mirae Asset Global Investments first reported a position in KLRS in Q3 2022 and held it in 6 quarters. The position peaked at $114K in Q3 2022. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • Mirae Asset Global Investments reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 527 Kalaris Therapeutics shares in Q2 2024, an estimated $48.6K.
  • Mirae Asset Global Investments first reported a position in Kalaris Therapeutics in Q3 2022 and held it in 6 quarters.
  • Mirae Asset Global Investments's Kalaris Therapeutics position peaked at $114K in Q3 2022.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.